cash and currency not needed Top searches

Italy's seasonally adjusted unemployment rate in the third quarter was 6.1%, and the previous value was 6.80%.President of Hilton Asia Pacific: India's outbound travel will be the story of the next decade. According to the data of the World Tourism and Travel Council, in 2023, Indian tourists spent $34.2 billion on outbound travel. Allen Watts, president of Hilton Asia Pacific, said that compared with the future, the current level of Indian outbound travel consumption is "negligible". "The story of India is unfolding before us," he said. "India's outbound travel will be the story of the next decade." According to the World Tourism and Travel Council's Economic Impact in 2024 report, by 2034, the outbound spending of Indian tourists is expected to more than double, reaching 76.8 billion US dollars, which will make India's position in the global tourism consumption country rise from the 12th in 2023 to the 7th.The national carbon market closed down 1.29% to 99.90 yuan/ton today. The comprehensive price of the national carbon market today is: the opening price is 101.15 yuan/ton, the highest price is 101.29 yuan/ton, the lowest price is 99.88 yuan/ton, and the closing price is 99.90 yuan/ton, which is 1.29% lower than the previous day. Today, the transaction volume of the listing agreement is 664,139 tons, with a turnover of 66,059,732.39 yuan; The volume of bulk agreement transactions was 8,504,320 tons, with a turnover of 841,280,251.88 yuan.

LambdaTest received $38 million in financing, and Qualcomm Venture Capital participated in the investment. On December 12th, LambdaTest, a unified cloud testing platform, announced that the company had received $38 million in financing led by Avataar Ventures and invested by Qualcomm Venture Capital, with a total financing amount of $108 million. Founded in 2017, LambdaTest has raised nearly $70 million from investors in previous rounds of financing, including Premji Invest, Sequoia Capital India, Titanium Ventures, Leo Capital Holdings and Blume Ventures.In the latest centralized purchase of sitagliptin tablets, the price dropped to less than 20 cents per tablet, with a drop of over 90%. The reporter learned at the scene of the tenth batch of drug centralized purchase that more than 30 companies bid for sitagliptin, which is known as the largest variety in this centralized purchase, including Huahai Pharmaceutical, Kelun Pharmaceutical, Zhengda Tianqing, tonghua dongbao, Zhejiang Pharmaceutical, Jiudian Pharmaceutical, Shiyao Ouyi, Chenxin Pharmaceutical and many other companies. Judging from the bidding results, the lowest bid price among enterprises has dropped below 0.2 yuan per piece, which is more than 90% lower than the limit price. Statistics show that in 2023, the sales of this product in the terminals of public medical institutions in China exceeded 2 billion yuan, and the sales of Merck, the original research manufacturer, accounted for more than 90%, so there is a large room for generic drug substitution. The quotation of Meradong in this collection is about 7.37 yuan per piece. (science and technology innovation board Daily)Zhongyuan Expressway: The toll revenue in November was 373 million yuan. Zhongyuan Expressway announced that the toll revenue in November 2024 was 373 million yuan.

President of the Swiss National Bank: We will continue to monitor inflationary pressure and adjust monetary policy to maintain price stability if necessary. The president of the Swiss National Bank said that we will continue to monitor inflationary pressure and adjust monetary policy to maintain price stability if necessary. If there is no interest rate cut today, inflation expectations will be lower; The uncertainty of the future inflation path is still high.Mengke Pharmaceutical Co., Ltd.: The new packaging of Contizontamide tablets will be on the market soon. Mengke Pharmaceutical Co., Ltd. announced that the company has launched Contizontamide tablets with new packaging specifications, and a box of 12 tablets will be on the market soon. Contizontamide tablet is a new class 1 oxazolidinone antibacterial drug with global intellectual property rights. It was approved by National Medical Products Administration, China on June 1st, 2021 for the treatment of complex skin and soft tissue infections.Schlegel, Governor of the Swiss National Bank: We will continue to monitor inflationary pressure and adjust monetary policy to maintain price stability if necessary. Without today's interest rate cut, inflation expectations would be lower. The uncertainty of the future inflation path is still high. The medium-term inflationary pressure has dropped significantly.